Quick response of advanced cancer to chemoradiation therapy with antineoplastons

Oncology Reports

Volumn 5, Issue 3, 1998, Pages 597-600

  Tsuda, Hideaki ^a   Sata, Michio ^a   Kumabe, Tsutomu ^a   Kara, Hiroshi ^a   Eriguchi, Naofumi ^a   Sugita, Yasuo ^a   Nagamatsu, Hiroaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced cancer; Antineoplastons; Combination; Cytotoxic conventional therapy; Rapid response

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; ANTINEOPLASTON AS2-1; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; NIMUSTINE;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PEPTIDE ANALYSIS; PRIORITY JOURNAL;

EID: 0031957413     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.3.597     Document Type: Article

References (11)

1. Burzynski SR: Antineoplastons: biochemical defense against cancer. Physiol Chem Phys 8: 275-279, 1976.
2. Ashraf AQ, Kampalath BN and Burzynski SR: Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats. Adv Exp Clin Chemother 6: 33-39, 1988.
3. Burzynski SR, Mohabbat MO and Lee SS: Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exp Clin Res 1 (Suppl): 25-28, 1986.
4. Tsuda H, lemura A, Sata M, Uchida M, Yamana K and Hara H: Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Medical J 43: 137-147, 1996.
5. Tsuda H, Sugihara S, Nishida H, Hara H, Eriguchi N, Ishii K, Sasaki K, Yoshimura S and Tanaka N: The inhibitory effect of the combination of antineoplaston A10 Injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma. Jpn J Cancer Res 83: 527-531, 1992.
6. Tsuda H, Hara H, Eriguchi N, Nishida H, Kumabe T and Sugita Y: Toxicology study on antineoplaston A10 and AS2-1 in cancer patients. Kurume Medical J 42: 241-246, 1996.
7. Burzynski SR: Potential of antineoplastons in diseases of old age. Drugs Aging?: 157-167, 1995.
8. Crooke ST, Du Vernay VH, Galvan L and Prestayko AW: Structure-activity relationships of anthracyclines relative to effects on macromolecular synthesis. Mol Pharmacol 14: 290-298, 1978.
9. Cohen GL, Bauer WR, Barton JK and Lippard SJ: Binding of cis-and mares-dichlordiammineplatinum (II) to DNA: Evidence for unwinding and shortening of the double helix. Science 203: 1014-1016, 1979.
10. The French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 6: 679-688, 1988.
11. Tsuda H, Sata M, Saitu H, Yamana K, Hara H, Yamada S and Kumabe T: Antineoplaston AS2-1 for maintenance therapy in liver cancer. Oncol Rep 4: 1213-1216, 1997.